Schrodinger, Inc. (SDGR)
Computer Software and Services • Information Technology
July 27, 2026 Schrödinger Unveils Bunsen: A Game-Changer in Molecular Discovery Schrödinger has launched Bunsen, an AI co-scientist designed to revolutionize molecular discovery. This platform enhances researchers' capabilities in drug development through advanced computational methods and strategic collaborations with NVIDIA and Google Cloud.
July 22, 2026 Schrödinger, Inc. Set to Release Q2 2026 Financial Results Schrödinger, Inc. will report its Q2 2026 financial results on August 5, 2026, followed by a conference call for stakeholders. The company is known for its innovative molecular discovery platform, crucial for drug development and materials science.
July 20, 2026 Schrödinger, Inc. Announces Inducement Grants for New Employees On July 20, 2026, Schrödinger, Inc. announced the granting of restricted stock units (RSUs) to attract new talent as part of its hiring strategy. The RSUs, totaling 3,691 shares, are designed to align employee and shareholder interests while promoting long-term commitment through a structured vesting schedule.
June 18, 2026 Schrödinger, Inc. Announces Inducement Grants to New Employees Schrödinger, Inc. has awarded 10,771 RSUs to seven new employees as part of its strategy to attract talent in the biotech industry. This initiative aligns employee interests with the company's long-term growth and retention goals.
May 22, 2026 Schrödinger, Inc. Announces Significant Employee Inducement Grants On May 22, 2026, Schrödinger, Inc. announced employee inducement grants to attract top talent, including stock options and RSUs. This strategic move aligns employee interests with the company's long-term goals in drug discovery and materials design.
May 05, 2026 Schrodinger, Inc. Reports Mixed Financial Results for Q1 2026 Schrodinger, Inc. reported mixed financial results for Q1 2026, with a slight revenue decline and increased net losses. The company showcases growth in annual contract value and strategic collaborations, positioning itself for future opportunities despite operational challenges.
May 05, 2026 Schrödinger Reports Strong First Quarter 2026 Financial Results Schrödinger, Inc. reported a 12% increase in annual contract value for Q1 2026, driven by improved customer engagement and drug discovery revenue growth. The company is transitioning to hosted software licensing while anticipating continued growth in drug discovery revenue and innovative AI solutions.
May 04, 2026 Schrödinger, Inc. to Engage Investors at Upcoming Conferences Schrödinger, Inc. will engage investors at the BofA and RBC Healthcare Conferences in May 2026, discussing innovations in drug discovery. Live streams will be available on their website.
April 17, 2026 Schrödinger, Inc. Announces Inducement Grants Under Nasdaq Listing Rule On April 17, 2026, Schrödinger, Inc. announced the granting of restricted stock units to new employees, reinforcing its strategy to attract talent. The RSUs come with a structured vesting schedule, aligning employee interests with company goals.
March 18, 2026 Schrödinger, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Schrödinger, Inc. announced inducement grants under Nasdaq Rule 5635(c)(4) to attract new talent. The grants include stock options and RSUs with a structured vesting plan, emphasizing long-term commitment and growth.
February 25, 2026 Schrodinger, Inc. Reports 2025 Annual Results: Growth Amidst Challenges Schrodinger, Inc. reported significant revenue growth for 2025, driven by its drug discovery and software segments, despite operational losses. The company is implementing restructuring strategies and maintaining strong partnerships to enhance future growth potential.
February 24, 2026 Schrödinger, Inc. to Showcase Innovations at Upcoming Investor Conferences Schrödinger, Inc. will participate in several investor conferences in March 2026, highlighting innovations in drug development and materials design. The events will feature live discussions and insights into the company’s strategic initiatives and computational advancements.
January 09, 2026 Schrödinger Partners with Lilly to Enhance Drug Discovery through TuneLab Integration Schrödinger has partnered with Eli Lilly to integrate Lilly's TuneLab platform into its LiveDesign environment, enhancing AI-driven drug discovery. This collaboration aims to democratize access to advanced computational tools, accelerating the development of innovative therapies.
December 17, 2025 Schrödinger Expands Workforce with Inducement Grants On December 15, 2025, Schrödinger, Inc. announced the granting of RSUs to six new employees to strengthen its workforce. This move is part of their competitive compensation strategy and aligns employee interests with long-term company goals. The RSUs will vest over four years, promoting retention and growth.
November 06, 2025 Schrödinger, Inc. to Participate in Jefferies London Healthcare Conference Schrödinger, Inc. will participate in the Jefferies London Healthcare Conference on November 19, 2025. The event will feature a live webcast of their fireside chat, showcasing their advancements in computational drug discovery.
November 05, 2025 Schrödinger Reports Strong Third Quarter 2025 Financial Results Schrödinger's Q3 2025 financial results show a 54% revenue growth, driven by strong demand for software and drug discovery. CEO Ramy Farid highlights a strategic pivot towards collaborations in therapeutics. The company remains optimistic about future growth despite macroeconomic challenges.
November 05, 2025 Schrodinger, Inc. Reports Q3 2025 Financial Results: A Year of Growth Amid Challenges Schrodinger, Inc. reports a robust 54% revenue growth in Q3 2025, reaching $54.3 million despite a net loss. The company focuses on advancing drug discovery while navigating operational challenges and restructuring for efficiency.
August 06, 2025 Schrodinger, Inc. Reports Q2 2025 Financial Results: Growth Amid Challenges Schrodinger, Inc. reported a 16% revenue increase to $54.8 million in Q2 2025, although it faced a net loss of $43.2 million. The company is focused on strategic collaborations and innovative drug discovery to enhance its market position despite ongoing challenges.
May 14, 2025 Schrödinger, Inc. Announces Phase 1 Clinical Data Presentation for MALT1 Inhibitor SGR-1505 Schrödinger, Inc. announces the presentation of Phase 1 clinical data for its MALT1 inhibitor SGR-1505 at major conferences in June 2025. This data will explore the safety and efficacy of SGR-1505 in treating relapsed/refractory B-cell malignancies, marking a significant advancement in oncology research.
May 07, 2025 Schrödinger Reports Strong First Quarter 2025 Financial Results Schrödinger, Inc. announced a 63% revenue increase for Q1 2025, with significant growth in both software and drug discovery sectors. The company is advancing its drug pipeline and maintaining a positive financial outlook despite a slight net loss.
May 07, 2025 Schrodinger, Inc. Reports Strong Q1 2025 Results Despite Increased Net Loss Schrodinger, Inc. reported a 63% revenue increase in Q1 2025, reaching $59.6 million, driven by its software and drug discovery segments. However, net losses rose to $59.8 million due to ongoing investments in R&D. The company maintains a strong cash position and is focused on advancing its drug discovery pipeline through strategic collaborations.
May 05, 2025 Schrödinger, Inc. to Showcase Innovations at BofA Securities 2025 Healthcare Conference Schrödinger, Inc. will present at the BofA Securities 2025 Healthcare Conference on May 14, discussing advancements in molecular discovery and oncology programs. The session will be available for live viewing and archived for 90 days.
April 28, 2025 Schrödinger Unveils Promising Preclinical Data at AACR 2025 At AACR 2025, Schrödinger presented groundbreaking preclinical data on SGR-3515 and SGR-4174, highlighting their superior anti-tumor activities and innovative approaches to cancer treatment. These findings signal significant advancements in targeted therapies that could reshape oncology.
April 23, 2025 Schrödinger, Inc. to Release First Quarter 2025 Financial Results Schrödinger, Inc. is set to announce its financial results for Q1 2025 on May 7, 2025. The accompanying conference call will provide insights into the company's performance and future strategies.
April 18, 2025 Schrödinger, Inc. Announces Inducement Grants to New Employees On April 16, 2025, Schrödinger, Inc. announced inducement grants for new hires as part of its strategy to attract top talent. The grants include stock options and RSUs, aimed at promoting long-term commitment and aligning employee interests with shareholders.
April 14, 2025 Schrödinger, Inc. Supports FDA Shift Towards Computational Drug Safety Schrödinger, Inc. endorses the FDA's initiative to phase out animal testing for drugs, emphasizing computational methods in drug safety. The company's predictive toxicology initiative aims to minimize development risks, showcasing its commitment to innovative drug discovery.
March 25, 2025 Schrödinger, Inc. Set to Present Groundbreaking Preclinical Data at AACR Annual Meeting 2025 Schrödinger, Inc. will present new preclinical data on SGR-3515 and SGR-4174 at the AACR Annual Meeting 2025. The findings highlight advancements in cancer treatment through optimized dosing and machine learning insights, aiming to improve outcomes for patients with advanced tumors and KRAS mutations.
March 10, 2025 Schrödinger, Inc. Welcomes Bridget van Kralingen to Board of Directors On March 10, 2025, Schrödinger, Inc. welcomed Bridget van Kralingen to its Board of Directors to enhance leadership and drive growth. With over 35 years of experience, her strategic insights are expected to benefit the company's ongoing innovation in drug development and materials discovery.
March 02, 2025 SWOT Analysis of Schrodinger, Inc. in 2025 This SWOT analysis of Schrodinger, Inc. in 2025 reveals its technological strengths and growth opportunities, while also addressing financial challenges and competitive threats. The company is well-positioned, yet must navigate hurdles to maintain its leading role in biotechnology.
February 26, 2025 Schrödinger, Inc. Reports 2024 Annual Results: A Year of Transformation and Challenges Schrödinger, Inc. reported a revenue decline in 2024, reflecting challenges in drug discovery despite gains in software. The company continues to focus on R&D and strategic partnerships to drive future growth.
February 24, 2025 Schrödinger, Inc. Set to Engage Investors at Key Upcoming Conferences Schrödinger, Inc. will participate in key investor conferences in March 2025, including TD Cowen and Leerink Partners. The events will focus on the company's strategic initiatives and innovations in drug development.
February 20, 2025 Schrödinger Grants Inducement Stock Options to New Employees On February 20, 2025, Schrödinger, Inc. announced the granting of RSUs to five new employees as part of its growth strategy in the competitive biotech sector. The inducement grants, totaling 5,445 shares, aim to attract top talent and foster long-term commitment through a structured vesting schedule.
February 12, 2025 Schrödinger, Inc. Set to Reveal Fourth Quarter and Full-Year 2024 Financial Results Schrödinger, Inc. is set to disclose its Q4 and full-year 2024 financial results on February 26, 2025. A conference call will follow to discuss the outcomes and provide insights into its molecular discovery advancements.
November 12, 2024 Schrödinger, Inc. Reports Q3 2024 Results: Challenges and Opportunities Ahead Schrödinger, Inc. reported a 17% revenue decline to $35.3 million in Q3 2024, with a net loss of $38.1 million. Despite challenges, advancements in clinical trials and collaborations signal potential for future growth.
July 31, 2024 Schrödinger, Inc. Reports Strong Revenue Growth in Q2 2024 Amid Increased Losses Schrödinger, Inc. reported a 35% increase in revenue to $47.3 million for Q2 2024, but faced significant losses of $54 million. The company continues to invest heavily in R&D and maintain strategic collaborations to drive its drug discovery initiatives.
May 01, 2024 Schrödinger, Inc. Reports Q1 2024 Financial Results: A Challenging Start to the Year Schrödinger, Inc. faces a challenging Q1 2024 with a 44% drop in revenue and a net loss of $54.7 million. Despite these setbacks, the company retains a solid liquidity position for ongoing R&D efforts.